Search Results - "Thomassen, M C L G D"

Venous Thrombosis and Changes of Hemostatic Variables during Cross-Sex Hormone Treatment in Transsexual People by Toorians, A. W. F. T., Thomassen, M. C. L. G. D., Zweegman, S., Magdeleyns, E. J. P., Tans, G., Gooren, L. J. G., Rosing, J.

“…The incidence of venous thrombosis associated with estrogen treatment in male-to-female (M→F) transsexuals is considerably higher with administration of oral…”
Get full text

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives by Rosing, J., Tans, G., Nicolaes, G. A. F., Thomassen, M. C. L. G. D., Van Oerle, R., Van DerPloeg, P. M. E. N., Heijnen, P., Hamulyak, K., Hemker, H. C.

“…Epidemiological studies have shown that women who use third‐generation oral contraceptives (OC) containing desogestrel, gestodene or norgestimate have a higher…”
Get full text

Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals by Nicolaes, G A, Thomassen, M C, Tans, G, Rosing, J, Hemker, H C

“…In this paper we describe the effect of activated protein C (APC) on thrombin generation initiated in platelet-poor plasma via the extrinsic or the intrinsic…”
Get more information

Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism by Tchaikovski, S.N., Thomassen, M.C.L.G.D., Stickeler, E., Bremme, K., Rosing, J.

“…Hormonal contraception is a well-known risk factor for venous thromboembolism (VTE). APC resistance and impaired functions of protein S and TFPI are thought to…”
Get full text

Effect of blood loss during caesarean section on coagulation parameters by Wasserloos, A., Thomassen, M.C.L.G.D., Costa, S.D., Zenclussen, A., Tchaikovski, V., Hackeng, T.M., Stickeler, E., Tchaikovski, S.N.

“…Venous thrombosis is the leading cause of pregnancy-related maternal morbidity and mortality. The thrombosis risk is increased by caesarean section and blood…”
Get full text

New functional assays to selectively quantify the activated protein C‐ and tissue factor pathway inhibitor‐cofactor activities of protein S in plasma by Alshaikh, N. A., Rosing, J., Thomassen, M. C. L. G. D., Castoldi, E., Simioni, P., Hackeng, T. M.

“…Essentials Protein S is a cofactor of activated protein C (APC) and tissue factor pathway inhibitor (TFPI). There are no assays to quantify separate APC and…”
Get full text

Tissue factor‐independent inhibition of thrombin generation by tissue factor pathway inhibitor‐α by Thomassen, M. C. L. G. D., Heinzmann, A. C. A., Herfs, L., Hartmann, R., Dockal, M., Scheiflinger, F., Hackeng, T. M., Rosing, J.

“…Summary Background Tissue factor pathway inhibitor‐α (TFPIα) inhibits factor Xa by forming a binary TFPI–FXa complex in a reaction that is stimulated by…”
Get full text

Effect of in vitro fertilization treatment and subsequent pregnancy on the protein C pathway by Curvers, J., Nap, A. W., Thomassen, M. C. L. G. D., Nienhuis, S. J., Hamulyák, K., Evers, J. L. H., Tans, G., Rosing, J.

“…Thirty‐three women who were planned for an in vitro fertilization (IVF) cycle donated blood at four time points during treatment: at baseline, after…”
Get full text

Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives by Tchaikovski, S.N, Thomassen, M.C.L.G.D, Costa, S.D, Bremme, K, Rosing, J

“…Abstract Introduction Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on the OC formulation and could at least partially be…”
Get full text

Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia by Tchaikovski, S N, Thomassen, M C L G D, Costa, S-D, Peeters, L L H, Rosing, J

“…Pregnancy increases the risk of venous thromboembolism. Particularly in early pregnancy, the thrombosis risk can be attributed to the changes in coagulation…”
Get more information

Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia by CASTOLDI, E., SIMIONI, P., TORMENE, D., THOMASSEN, M. C. L. G. D., SPIEZIA, L., GAVASSO, S., ROSING, J.

“…Background: Hyperprothrombinemia, resulting from the prothrombin G20210A mutation or other causes, is associated with activated protein C (APC) resistance and…”
Get full text

Pregnancy‐associated changes in the hemostatic system in wild‐type and factor V Leiden mice by TCHAIKOVSKI, S. N., VAN VLIJMEN, B. J. M., CLEUREN, A. C. A., THOMASSEN, M. C. L. G. D., TCHAIKOVSKI, V., TANS, G., ROSING, J.

“…Background: Pregnancy, oral contraceptive (OC) use and hormone replacement therapy (HRT) are established risk factors for venous thrombosis. Acquired…”
Get full text

Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-[alpha] by Thomassen, M C L G D, Heinzmann, A C A, Herfs, L, Hartmann, R, Dockal, M, Scheiflinger, F, Hackeng, T M, Rosing, J

“…Summary Background Tissue factor pathway inhibitor-[alpha] (TFPI[alpha]) inhibits factor Xa by forming a binary TFPI-FXa complex in a reaction that is…”
Get full text

Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography by Tchaikovski, Svetlana N, van Vliet, Huib A A M, Thomassen, M C L G D, Bertina, Rogier M, Rosendaal, Frits R, Sandset, Per-Morten, Helmerhorst, Frans M, Tans, Guido, Rosing, Jan

“…In a study population consisting of healthy men (n = 8), women not using oral contraceptives (OC) (n = 28) and women using different kinds of OC (n = 187) we…”
Get more information

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study by Rosing, Jan, Middeldorp, Saskia, Curvers, Joyce, Thomassen, M Christella L GDlig, Nicolaes, Gerry AF, Meijers, Joost CM, Bouma, Bonno N, Büller, Harry R, Prins, Martin H, Tans, Guido

“…We have reported previously that, compared with use of second-generation oral contraceptives, the use of third-generation oral contraceptives is associated…”
Get full text

Peptides Binding to Kunitz Domain 1 of Tissue Factor Pathway Inhibitor (TFPI) Inhibit All Functions of TFPI and Improve Thrombin Generation of Hemophilia Plasma by Dockal, Michael, Brandstetter, Johannes, Ludwiczek, Martin, Kontaxis, Georg, Fries, Markus, Thomassen, M C L G D, Heinzmann, A, Ehrlich, Hartmut J., Prohaska, Katerina, Hartmann, Rudolf, Rosing, Jan, Scheiflinger, Friedrich

“…Abstract 2245 Blood coagulation is initiated by the tissue factor-factor VIIa (TF-FVIIa) complex which cleaves and activates coagulation factor X to Xa (FXa)…”
Get full text

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways by Tans, G, Curvers, J, Middeldorp, S, Thomassen, M C, Meijers, J C, Prins, M H, Bouma, B N, Büller, H R, Rosing, J

“…The use of oral contraceptives (OC) causes disturbances of the procoagulant, anticoagulant and fibrinolytic pathways of blood coagulation which may contribute…”
Get more information

Acquired APC resistance and oral contraceptives: differences between two functional tests by Curvers, Joyce, Thomassen, M. Christella L. G. D., Nicolaes, Gerry A. F., Van Oerle, Rene, Hamulyak, Karly, Coenraad HEMKER, H., Tans, Guido, Rosing, Jan

“…Resistance to activated protein C (APC) is often associated with a mutation in factor V (factor VLeiden). Individuals without factor VLeiden who exhibit a…”
Get full text

Characterization of two forms of human factor Va with different cofactor activities by ROSING, J, BAKKER, H. M, THOMASSEN, M. C. L. G. D, HEMKER, H. C, TANS, G

“…Factor Va is an essential cofactor in factor Xa-catalyzed prothrombin activation. Purified human factor Va appears to consist of a heavy chain (M(r)…”
Get full text

Activation of human factor V by meizothrombin by TANS, G, NICOLAES, G. A. F, THOMASSEN, M. C. L. G. D, VAN ZONNEVELD, A.-J, PANNEKOEK, H, ROSING, J

“…A recombinant human prothrombin was prepared in which Arg155 was replaced by Ala. The recombinant prothrombin was converted into a meizothrombin derivative…”
Get full text